Alliance Pharma PLC Notification of Preliminary Results (8989E)
February 16 2015 - 2:01AM
UK Regulatory
TIDMAPH
RNS Number : 8989E
Alliance Pharma PLC
16 February 2015
For immediate release 16 February 2015
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Notification of Preliminary Results
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, will announce its preliminary results for the year ended
31 December 2014 on Wednesday 25 March 2015.
A briefing for analysts will be held at 11.00am on the morning
of the results at the offices of Buchanan, 107 Cheapside, London
EC2V 6DN.
For more information please contact Buchanan on 020 7466
5000.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan + 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane
Glover
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade /
Freddie Barnfield
Corporate Broking: David Poutney
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has a strong track record of acquiring the rights to
established niche products and owns or licenses the rights to more
than 60 pharmaceutical products and continues to explore
opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFLSFDIVLIE
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024